Novel Role for Osteopontin in Cardiac Fibrosis
2008; Lippincott Williams & Wilkins; Volume: 102; Issue: 3 Linguagem: Inglês
10.1161/circresaha.107.170555
ISSN1524-4571
Autores Tópico(s)Electrospun Nanofibers in Biomedical Applications
ResumoHomeCirculation ResearchVol. 102, No. 3Novel Role for Osteopontin in Cardiac Fibrosis Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBNovel Role for Osteopontin in Cardiac Fibrosis Peter Zahradka Peter ZahradkaPeter Zahradka From the University of Manitoba and St. Boniface Research Centre, Winnipeg, Canada. Originally published15 Feb 2008https://doi.org/10.1161/CIRCRESAHA.107.170555Circulation Research. 2008;102:270–272Wound healing is a normal physiological process that is required for the repair of tissue damage.1 The initial stages of this process result in the formation of a scar through deposition of extracellular matrix (ECM) proteins. In the subsequent stages, scar tissue is slowly replaced by new cells. The final result is regeneration of the original tissue and significant restoration of function.The primary mediator of wound healing is the fibroblast, a nondescript cell found in all tissues.2 Activated fibroblasts or myofibroblasts are the source of the ECM proteins that form the scar. Myofibroblasts also help to maintain the integrity of the damaged tissue by contracting the newly deposited ECM, thus promoting wound closure. The scar subsequently serves as a matrix for cell recolonization during tissue regeneration. Accordingly, the scar is a temporary structure that is slowly removed as new cells are produced. Once regeneration is complete, the myofibroblasts revert to their original inactive state.The interconversion of fibroblasts and myofibroblasts is intended to enable a rapid response to injury while ensuring excessive ECM deposition or fibrotic scarring does not occur. Nevertheless, failure to terminate the wound-healing program, thus leading to persistent activation of fibroblasts, does happen, and is the primary cause of fibrotic disease.2,3 Because excessive scar production or fibrosis can seriously compromise organ function, there is considerable effort underway to identify methods of preventing this currently untreatable condition.Unlike most tissues, the heart is unable to repair itself because of the lack of sufficient cardiomyocyte proliferation. Consequently, neither scar removal nor regeneration occurs following a myocardial infarction. Nevertheless, wound healing plays a critical role in maintaining adequate heart function in the face of tissue loss.4 More specifically, the presence of the scar aids with myocardial remodeling, the adaptive change in heart morphology that is necessary for successful continuation of its function in the face of the restrictions placed on its pumping capability. On the other hand, because of the lack of scar flexibility, contraction of the heart places continual stress on the viable myocardial tissue that surrounds the scar, and this maintains fibroblasts in their activated state. As a result, there is chronic ECM deposition by myofibroblasts and further expansion of the scar. Eventually, the scar begins to interfere with cardiac compliance, thus further impairing function and instigating additional remodeling that in due course leads to failure.4Mechanical stress and angiotensin II, which is released from injured cardiomyocytes, can trigger the activation of fibroblasts. In a process that parallels the phenotypic modulation of smooth muscle cells,5 fibroblasts with limited proliferative capacity undergo a conversion to myofibroblasts, which are capable of proliferation, migration, and ECM protein synthesis. The change in fibroblast properties is initiated by transformation growth factor (TGF)-β.6 This cytokine is produced in response to cellular damage and hormones such as angiotensin II. TGF-β, in turn, stimulates the expression of genes that are characteristic of myofibroblasts, including α-smooth muscle actin, ED-A fibronectin, connective tissue growth factor (CTGF), and osteopontin (OPN).OPN is a phosphoprotein identified originally in osteoblasts and osteoclasts but has since been shown to be secreted by many different cell types.7 Although initially linked to bone mineralization, it is now recognized that OPN promotes cell adhesion and can mediate immune responses.8 OPN is not found in the unstressed heart; however, several studies from the laboratory of Hsueh in the late 1990s established that OPN expression correlated with onset of cardiac hypertrophy,9 presumably as a result of fibroblast activation.10 At approximately the same time, a correlation between OPN and onset of heart failure was also reported.11 Later studies demonstrated that OPN was necessary for maintaining effective cardiac function, because animals lacking OPN exhibit exaggerated left ventricular hypertrophy.12 Regardless, it has been generally accepted that OPN operates in the postinfarct heart by coordinating the intercellular signals required to integrate myofibroblast proliferation, migration, and ECM deposition with the recruitment of macrophages and initiation of collateral vessel formation, thus ensuring the mechanical properties of the heart are not compromised further.Whereas it is generally accepted that the cardiac functions of OPN require its secretion by myofibroblasts,13 Lenga et al14 recently examined the premise that OPN has a more active role in the formation of the myofibroblastic state. In this issue of Circulation Research, the authors identified a causal relationship between OPN expression and differentiation of fibroblasts into myofibroblasts. The concept that OPN was required for modulating fibroblast activation was based, in part, on the observation that α-smooth muscle actin is not expressed in TGF-β–treated cardiac fibroblasts isolated from OPN-null mice. This single finding establishes that OPN is absolutely required for expression of the myofibroblast phenotype and was confirmed by small interfering RNA knockdown of OPN in fibroblasts from wild-type mice.Other markers of myofibroblast differentiation were also monitored by Lenga et al.14 It was found that CTGF expression, formation of stress fibers, and focal adhesion, contractility, adhesion, and cell spreading were altered in the absence of OPN. In general, fibroblasts from OPN−/− mice retained a rounder morphology because of the presence of fewer adhesions. Nevertheless, these cells were still responsive to the chemoattractant actions of TGF-β, as determined in a migration assay, indicating that this property was unaffected. On examining the components of the adhesion complexes by mass spectrometry, Lenga et al14 found that HMGB1 (high-mobility group box 1 protein) was present in the focal adhesions of wild-type fibroblasts but not detectable in the absence OPN. In cells from OPN−/− mice, HMGB1 was located solely in the nucleus.HMGB1 is a nonhistone chromosomal protein that was initially isolated more than 30 years ago.15 More recently, it has been reported that HMGB1 is a proinflammatory cytokine released by activated macrophages.15 On release, it can bind to RAGE, the receptor for activated glycation products, and stimulate the release of proinflammatory cytokines. Interestingly, HMGB1 may have a dual function in the heart: to enhance progression of ischemic injury16 and to promote cardiac regeneration through recruitment of stem cells.17 Based on these properties, it is likely that HMGB1 serves to mediate the immune response attributed to OPN. With respect to Lenga et al,14 no evidence was provided to suggest HMGB1 is released from myofibroblasts, although such a result may be predicted. However, it is also plausible that sequestration of HMGB1 in focal adhesions has specific effects on gene expression that promote fibroblast differentiation (Figure). It is also possible that the interaction between OPN and HMGB1 is a general phenomenon that modulates their functions, because it was recently shown that OPN can also shuttle between the nucleus and cytoplasm.18Download figureDownload PowerPointFigure. Regulatory processes associated with fibroblast differentiation that are mediated by OPN. FA indicates focal adhesion.The other unique finding made by Lenga et al14 is the fact that OPN controls CTGF expression. It has been established that both OPN and CTGF are induced by the binding of SMAD proteins to their respective promoters following treatment with TGF-β.19,20 However, Chen et al21 have shown that the extracellular signal-regulated kinase pathway must also be activated for induction of the CTGF gene expression. Based on the findings of Lenga et al,14 it is likely that OPN performs this function, but whether activation of extracellular signal-regulated kinase via focal adhesion kinase22 is the mechanism through which OPN operates still remains to be determined. A role for integrin-linked kinase in this process, however, appears unlikely.23The study by Lenga et al14 has provided a unique insight into the mechanisms that control fibroblast differentiation in response to TGF-β. Not only has a novel regulatory mechanism for CTGF expression been formulated, a new factor, HMGB1, has been identified that likely integrates the key immunogenic events that participate in the cardiac response to injury. However, addressing these issues also has led to further questions. More details regarding the role of OPN in CTGF gene expression are called for. In particular, the role of focal adhesion activation in this process needs to be explored. Likewise, how does OPN modulate the cellular location of HMGB1, and is this protein secreted by cardiac myofibroblasts? In parallel, does HMGB1 mediate the expression of genes essential for differentiation of fibroblasts into myofibroblasts? Finally, does OPN function through its adhesive domains postsecretion, or does it operate via an intracellular mechanism? Lenga et al14 have done a significant service by making us aware that OPN acts as a humoral factor responsible for integrating the processes that maintain cardiac function postinfarction. This report is certain to generate significant interest in resolving these issues.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.Sources of FundingThis work was supported by the Canadian Institutes of Health Research.DisclosuresNone.FootnotesCorrespondence to Peter Zahradka, St. Boniface Research Centre, Canadian Centre for Agri-food Research in Health & Medicine, 351 Tache Ave, Winnipeg, MB R2H 2A6, Canada. E-mail [email protected] References 1 Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci. 2004; 9: 283–289.CrossrefMedlineGoogle Scholar2 Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast. One function, multiple origins. Am J Pathol. 2007; 170: 1807–1816.CrossrefMedlineGoogle Scholar3 Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther. 2007; 9 (suppl 2): S4.CrossrefMedlineGoogle Scholar4 Struthers AD. Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients. Heart. 2006; 92: 1728–1731.CrossrefMedlineGoogle Scholar5 Rzucidlo EM, Martin KA, Powell RJ. Regulation of vascular smooth muscle cell differentiation. J Vasc Surg. 2007; 45 (suppl A): A25–A32.CrossrefMedlineGoogle Scholar6 Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res. 2007; 74: 207–212.CrossrefMedlineGoogle Scholar7 Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001; 107: 1055–1061.CrossrefMedlineGoogle Scholar8 Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin–a molecule for all seasons. QJM. 2002; 95: 3–13.CrossrefMedlineGoogle Scholar9 Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, Hsueh WA. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation. 1997; 96: 3063–3071.CrossrefMedlineGoogle Scholar10 Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, Tuan TL, Hsueh WA. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest. 1996; 98: 2218–2227.CrossrefMedlineGoogle Scholar11 Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW, Bing OH, Colucci WS. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension. 1999; 33: 663–670.CrossrefMedlineGoogle Scholar12 Trueblood NA, Xie Z, Communal C, Sam F, Ngoy S, Liaw L, Jenkins AW, Wang J, Sawyer DB, Bing OH, Apstein CS, Colucci WS, Singh K. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res. 2001; 88: 1080–1087.CrossrefMedlineGoogle Scholar13 Scatena M, Liaw L, Giachelli CM. Osteopontin. A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007; 27: 2302–2309.LinkGoogle Scholar14 Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ Res. 2008; 102: 319–327.LinkGoogle Scholar15 Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med. 2004; 255: 320–331.CrossrefMedlineGoogle Scholar16 Woo YJ, Taylor MD, Cohen JE, Jayasankar V, Bish LT, Burdick J, Pirolli TJ, Berry MF, Hsu V, Grand T. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J Thorac Cardiovasc Surg. 2004; 127: 1262–1269.CrossrefMedlineGoogle Scholar17 Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004; 164: 441–449.CrossrefMedlineGoogle Scholar18 Junaid A, Moon MC, Harding GE, Zahradka P. Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol. 2007; 292: C919–C926.CrossrefMedlineGoogle Scholar19 Leask A, Sa S, Holmes A, Shiwen X, Black CM, Abraham DJ. The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol. 2001; 54: 180–183.CrossrefMedlineGoogle Scholar20 Hullinger TG, Pan Q, Viswanathan HL, Somerman MJ. TGFbeta and BMP-2 activation of the OPN promoter: roles of. Exp Cell Res. 2001; 262: 69–74.CrossrefMedlineGoogle Scholar21 Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int. 2002; 62: 1149–1159.CrossrefMedlineGoogle Scholar22 Mori S, Takemoto M, Yokote K, Asaumi S, Saito Y. Hyperglycemia-induced alteration of vascular smooth muscle phenotype. J Diabetes Complications. 2002; 16: 65–68.CrossrefMedlineGoogle Scholar23 Graness A, Giehl K, Goppelt-Struebe M. Differential involvement of the integrin-linked kinase (ILK) in RhoA-dependent rearrangement of F-actin fibers and induction of connective tissue growth factor (CTGF). Cell Signal. 2006; 18: 433–440.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Sun S, Ni S, Li Y, Liu X, Deng J, Chen Z, Li H, Feng W, Huang Y, Li D, Xian S, Yang Z, Wang L and Lu L (2021) G-MDSCs promote aging-related cardiac fibrosis by activating myofibroblasts and preventing senescence, Cell Death & Disease, 10.1038/s41419-021-03874-7, 12:6, Online publication date: 1-Jun-2021. Mohseni Z, Derksen E, Oben J, Al-Nasiry S, Spaanderman M and Ghossein-Doha C (2021) Cardiac dysfunction after preeclampsia; an overview of pro- and anti-fibrotic circulating effector molecules, Pregnancy Hypertension, 10.1016/j.preghy.2020.12.001, 23, (140-154), Online publication date: 1-Mar-2021. Suthahar N, Meems L, Ho J and Boer R (2020) Sex‐related differences in contemporary biomarkers for heart failure: a review, European Journal of Heart Failure, 10.1002/ejhf.1771, 22:5, (775-788), Online publication date: 1-May-2020. Yang X, Li G, Yang T, Guan M, An N, Yang F, Dai Q, Zhong C, Luo C, Gao Y, Das S, Xing Y, Shang H and Sala V (2020) Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity, Oxidative Medicine and Cellular Longevity, 10.1155/2020/4894625, 2020, (1-30), Online publication date: 13-Oct-2020. Tarbit E, Singh I, Peart J and Rose'Meyer R (2018) Biomarkers for the identification of cardiac fibroblast and myofibroblast cells, Heart Failure Reviews, 10.1007/s10741-018-9720-1, 24:1, (1-15), Online publication date: 1-Jan-2019. Morse C, Tabib T, Sembrat J, Buschur K, Bittar H, Valenzi E, Jiang Y, Kass D, Gibson K, Chen W, Mora A, Benos P, Rojas M and Lafyatis R (2019) Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis, European Respiratory Journal, 10.1183/13993003.02441-2018, 54:2, (1802441), Online publication date: 1-Aug-2019. Coculescu B, Manole G, Dincă G, Coculescu E, Berteanu C and Stocheci C (2019) Osteopontin – a biomarker of disease, but also of stage stratification of the functional myocardial contractile deficit by chronic ischaemic heart disease, Journal of Enzyme Inhibition and Medicinal Chemistry, 10.1080/14756366.2019.1587418, 34:1, (783-788), Online publication date: 1-Jan-2019. Brandt M, Nguyen I, Krebber M, Wouw J, Mokry M, Cramer M, Duncker D, Verhaar M, Joles J and Cheng C (2019) Limited synergy of obesity and hypertension, prevalent risk factors in onset and progression of heart failure with preserved ejection fraction, Journal of Cellular and Molecular Medicine, 10.1111/jcmm.14542, 23:10, (6666-6678), Online publication date: 1-Oct-2019. Gawlik K, Holmberg J, Svensson M, Einerborg M, Oliveira B, Deierborg T and Durbeej M (2017) Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy, Scientific Reports, 10.1038/srep44059, 7:1, Online publication date: 1-Apr-2017. Uchibori T, Matsuda K, Shimodaira T, Sugano M, Uehara T and Honda T (2017) IL-6 trans-signaling is another pathway to upregulate Osteopontin, Cytokine, 10.1016/j.cyto.2016.11.006, 90, (88-95), Online publication date: 1-Feb-2017. Rouf R, MacFarlane E, Takimoto E, Chaudhary R, Nagpal V, Rainer P, Bindman J, Gerber E, Bedja D, Schiefer C, Miller K, Zhu G, Myers L, Amat-Alarcon N, Lee D, Koitabashi N, Judge D, Kass D and Dietz H (2017)(2017)(2017)(2017) Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan mice, JCI Insight, 10.1172/jci.insight.91588, 2:15, Online publication date: 3-Aug-2017., Online publication date: 3-Aug-2017., Online publication date: 3-Aug-2017., Online publication date: 3-Aug-2017. Huerta A, López B, Ravassa S, José G, Querejeta R, Beloqui Ó, Zubillaga E, Rábago G, Brugnolaro C, Díez J and González A (2016) Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients, Journal of Hypertension, 10.1097/HJH.0000000000000757, 34:1, (130-138), Online publication date: 1-Jan-2016. Passmore M, Nataatmadja M, Fung Y, Pearse B, Gabriel S, Tesar P and Fraser J (2015) Osteopontin alters endothelial and valvular interstitial cell behaviour in calcific aortic valve stenosis through HMGB1 regulation, European Journal of Cardio-Thoracic Surgery, 10.1093/ejcts/ezv244, 48:3, (e20-e29), Online publication date: 1-Sep-2015. Mohamed I and Mraiche F (2015) Targeting Osteopontin, the Silent Partner of Na + /H + Exchanger Isoform 1 in Cardiac Remodeling , Journal of Cellular Physiology, 10.1002/jcp.24958, 230:9, (2006-2018), Online publication date: 1-Sep-2015. Nishimura Y, Morikawa Y, Kondo C, Tonomura Y, Fukushima R, Torii M and Uehara T (2013) Genomic biomarkers for cardiotoxicity in rats as a sensitive tool in preclinical studies, Journal of Applied Toxicology, 10.1002/jat.2867, 33:10, (1120-1130), Online publication date: 1-Oct-2013. Xu D, Zhang T, Chen X, Zhou Q, Liu C, Deng Z, Zhang L, Ying C, Zhang W and Gu M (2013) Reduction of Osteopontin In Vivo Inhibits Tubular Epithelial to Mesenchymal Transition in Rats With Chronic Allograft Nephropathy, Transplantation Proceedings, 10.1016/j.transproceed.2012.02.048, 45:2, (659-665), Online publication date: 1-Mar-2013. Zheng Y, Wang Z, Deng L, Yuan X, Ma Y, Zhang G, Gantier M, Liu J, Shen L and Xu D (2012) Osteopontin promotes inflammation in patients with acute coronary syndrome through its activity on IL-17 producing cells, European Journal of Immunology, 10.1002/eji.201242475, 42:10, (2803-2814), Online publication date: 1-Oct-2012. Jin Y, Han H, Berger J, Dai Q and Lindsey M (2011) Combining experimental and mathematical modeling to reveal mechanisms of macrophage-dependent left ventricular remodeling, BMC Systems Biology, 10.1186/1752-0509-5-60, 5:1, (60), . Mori Y, Kondo C, Tonomura Y, Torii M and Uehara T (2010) Identification of potential genomic biomarkers for early detection of chemically induced cardiotoxicity in rats, Toxicology, 10.1016/j.tox.2010.02.015, 271:1-2, (36-44), Online publication date: 1-Apr-2010. Bogaard H, Natarajan R, Mizuno S, Abbate A, Chang P, Chau V, Hoke N, Kraskauskas D, Kasper M, Salloum F and Voelkel N (2010) Adrenergic Receptor Blockade Reverses Right Heart Remodeling and Dysfunction in Pulmonary Hypertensive Rats, American Journal of Respiratory and Critical Care Medicine, 10.1164/rccm.201003-0335OC, 182:5, (652-660), Online publication date: 1-Sep-2010. Singh M, Foster C, Dalal S and Singh K (2010) Role of osteopontin in heart failure associated with aging, Heart Failure Reviews, 10.1007/s10741-010-9158-6, 15:5, (487-494), Online publication date: 1-Sep-2010. Singh M, Foster C, Dalal S and Singh K (2010) Osteopontin: Role in extracellular matrix deposition and myocardial remodeling post-MI, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2009.06.015, 48:3, (538-543), Online publication date: 1-Mar-2010. Matsui Y (2010) Role of matricellular proteins in cardiac tissue remodeling after myocardial infarction, World Journal of Biological Chemistry, 10.4331/wjbc.v1.i5.69, 1:5, (69), . Roy S, Khanna S, Azad A, Schnitt R, He G, Weigert C, Ichijo H and Sen C (2010) Fra-2 mediates oxygen-sensitive induction of transforming growth factor β in cardiac fibroblasts, Cardiovascular Research, 10.1093/cvr/cvq123, 87:4, (647-655), Online publication date: 1-Sep-2010., Online publication date: 1-Sep-2010. Ying Z, Yue P, Xu X, Zhong M, Sun Q, Mikolaj M, Wang A, Brook R, Chen L and Rajagopalan S (2009) Air pollution and cardiac remodeling: a role for RhoA/Rho-kinase, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.01270.2008, 296:5, (H1540-H1550), Online publication date: 1-May-2009. Francia P, Uccellini A, Frattari A, Modestino A, Ricotta A, Balla C, Scialla L and Volpe M (2009) Extracellular Matrix Remodelling in Myocardial Hypertrophy and Failure, High Blood Pressure & Cardiovascular Prevention, 10.2165/11530450-000000000-00000, 16:4, (195-199), Online publication date: 1-Dec-2009. Chen C, Cheng C, Chen Y, Sue Y, Liu C, Cheng T, Hsu Y, Chen T and Han W (2014) MicroRNA-328 Inhibits Renal Tubular Cell Epithelial-to-Mesenchymal Transition by Targeting the CD44 in Pressure-Induced Renal Fibrosis, PLoS ONE, 10.1371/journal.pone.0099802, 9:6, (e99802) Abdelaziz Mohamed I, Gadeau A, Hasan A, Abdulrahman N and Mraiche F (2019) Osteopontin: A Promising Therapeutic Target in Cardiac Fibrosis, Cells, 10.3390/cells8121558, 8:12, (1558) Abdalrhim A, Marroush T, Austin E, Gersh B, Solak N, Rizvi S, Bailey K, Kullo I and Mischak H (2016) Plasma Osteopontin Levels and Adverse Cardiovascular Outcomes in the PEACE Trial, PLOS ONE, 10.1371/journal.pone.0156965, 11:6, (e0156965) February 15, 2008Vol 102, Issue 3 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCRESAHA.107.170555PMID: 18276921 Originally publishedFebruary 15, 2008 KeywordsosteopontinHMGB1myofibroblast differentiationcardiac fibrosisPDF download Advertisement
Referência(s)